MARKET

ISR

ISR

ISORAY
AMEX

Real-time Quotes | Nasdaq Last Sale

0.8000
+0.0289
+3.75%
After Hours: 0.8000 0 0.00% 17:46 05/17 EDT
OPEN
0.7600
PREV CLOSE
0.7711
HIGH
0.8000
LOW
0.7500
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
2.810
52 WEEK LOW
0.3520
MARKET CAP
113.17M
P/E (TTM)
-17.2043
1D
5D
1M
3M
1Y
5Y
Isoray posts FQ3 revenue slide, wider loss
Isoray (ISR) posted a slide in its fiscal third-quarter revenue, as the company dealt with weak performance from its core prostate brachytherapy business.Revenue for the third quarter declined 10% to $2.60M
Seekingalpha · 4d ago
BRIEF-Isoray Announces Third Quarter Fiscal 2021 Financial Results
reuters.com · 4d ago
IsoRay EPS in-line, beats on revenue
IsoRay (ISR): Q3 GAAP EPS of -$0.01 in-line.Revenue of $2.6M (-9.7% Y/Y) beats by $0.19M.Cash, cash equivalents, and certificates of deposit at the end of the third quarter of fiscal
Seekingalpha · 4d ago
IsoRay, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / IsoRay, Inc. (AMEX:ISR) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 4d ago
-- Earnings Flash (ISR) ISORAY Reports Q3 Revenue $2.6M, vs. Street Est of $2.42M
MT Newswires · 4d ago
Bard Associates Inc Buys Postal Realty Trust Inc, Isoray Inc, Piedmont Lithium Inc, Sells ...
GuruFocus News · 4d ago
-- Earnings Flash (ISR) ISORAY Posts Q3 Loss $-0.01, vs. Street Est of $-0.01
MT Newswires · 4d ago
IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates
Zacks.com · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISR. Analyze the recent business situations of ISORAY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ISR stock price target is 2.167 with a high estimate of 3.000 and a low estimate of 1.600.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 3.97M
% Owned: 2.81%
Shares Outstanding: 141.47M
TypeInstitutionsShares
Increased
3
180.54K
New
3
75.96K
Decreased
3
935.88K
Sold Out
6
261.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Michael McCormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Chief Accounting Officer/Controller
Mark Austin
Vice President/Director of Sales/Director of Marketing
Donna Fort
Vice President - Business Development
Lisa Lauer
Other
William Cavanagh
Secretary
Krista Cline
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
No Data
About ISR
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.